儿童侵袭性霉菌感染:进展与未解难题
本文综述免疫受损儿童侵袭性霉菌感染(IMI)诊断与治疗的最新进展与障碍。诊断仍依赖影像、微生物学与组织病理学,半乳甘露聚糖等生物标志物及分子检测有前景但需考虑局限性;新型抗真菌药与免疫治疗拓宽选择,但儿童数据有限,需持续儿科研究指导临床实践。
要点
- 儿童IMI诊断仍以影像、微生物学和组织病理学为基础,但敏感性和采样风险限制明显。
- 半乳甘露聚糖等非培养生物标志物有诊断价值,但解读需考虑试验局限与患者因素。
- 新型抗真菌药和免疫治疗拓宽选择,但儿童数据有限,需儿科研究支持。
核心结论
- 儿童IMI诊治已取得进展,但诊断工具与治疗选择的儿科证据仍不足,需持续研究优化临床实施。
研究设计与样本
- 综述:通过PubMed综合检索儿童IMI诊断与管理相关临床和临床前研究、共识指南及综述。
主要发现
- 胸部CT常为初始诊断依据,但影像非霉菌感染特异,不能区分侵袭性曲霉病与非曲霉霉菌。
- FDG-PET可能具优势,但诊断性采样仍必不可少。
- 血液、体液和组织样本的传统微生物学与组织病理学检查仍是实验室诊断支柱,但受敏感性、周转时间及侵入性采样并发症限制。
- 半乳甘露聚糖等非培养生物标志物有诊断作用,但解读需考虑试验局限与患者因素。
- 分子检测展现前景,未来将成为重要诊断工具;新型抗真菌药和免疫治疗有潜力但儿童数据有限。
临床怎么用
- 儿童IMI诊断需结合影像、微生物学、组织病理学及生物标志物综合判断,并认识各方法局限性。
- 新型抗真菌药和免疫治疗在儿童中应用需谨慎,应基于有限儿科数据并鼓励参与儿科研究。
局限性
- 综述指出儿童IMI诊断工具敏感性和采样风险存在局限,新型药物与免疫治疗儿科数据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Invasive mould infection (IMI) is a major cause of morbidity and mortality in immunocompromised children. Outcomes for paediatric patients with IMI remain poor, due in part to the limitations of available diagnostic tools and therapeutic agents. OBJECTIVES: To summarize current and emerging modalities for diagnosis and treatment of IMI in immunocompromised children, focusing on recent advances and remaining barriers. SOURCES: A comprehensive literature search of tools for diagnosis and management of IMI in children was conducted using PubMed, including clinical and preclinical studies, relevant consensus guidelines, and reviews. CONTENT: Initial diagnosis of IMI, particularly for invasive aspergillosis (IA), often relies on computed tomography imaging of the chest, yet imaging findings are not specific to mould infection and cannot differentiate between IA and nonaspergillus moulds. Fluorodeoxyglucose-positron emission tomography imaging may have advantages, but diagnostic sampling remains essential. Traditional microbiological and histopathological work up of blood, fluid and tissue samples are the mainstay of laboratory diagnosis of IMI in children, yet limitations related to test sensitivity, turnaround time, as well as potential complications associated with invasive sampling remain. Nonculture-based biomarkers, including galactomannan for IA, have a role in diagnosis of paediatric IMI, although interpretation requires consideration of test limitations and patient factors. Molecular assays have shown promise and will be an important diagnostic tool in future. Novel antifungal agents, including isavuconazole, olorofim, fosmanogepix, and ibrexafungerp, have significantly broadened the range of agents with activity against IMI, yet paediatric data are required to facilitate use in children. Similarly, immunotherapeutic approaches have potential to improve outcomes in paediatric IMI, yet data in children remain limited. IMPLICATIONS: There has been much progress in IMI management with recent development of novel diagnostic methods, new antifungals, and immunotherapeutic approaches. Ongoing paediatric studies are required to inform optimal implementation of these tools into clinical practice.
引用
- Yeoh DK, Butters C, Clark JE, et al. Invasive mould infection in children - advances made or obstacles remaining? Clin Microbiol Infect. 2025. PMID: 41317867. doi:10.1016/j.cmi.2025.11.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。